Muhamad Farid Zulkifle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Muhamad Farid Zulkifle has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Azly Sumanty Ab Ghani
Department of Pathology Hospital Sultanah Nur Zahirah, Ministry of Health Terengganu Malaysia
2 shared publications- Betty Lee-Sue Ho
Department of Pediatrics Hospital Umum Sarawak, Ministry of Health Sarawak Malaysia
2 shared publications Durar Aqilah Zamri
Genetics Department Hospital Tunku Azizah, Ministry of Health Kuala Lumpur Malaysia
2 shared publications- Ezalia Esa
Cancer Research Centre, Institute for Medical Research, National Institutes of Health, Ministry of Health, Selangor, Malaysia
2 shared publications Nazzlin Dizana Din
Department of Pediatrics Hospital Sultanah Nur Zahirah, Ministry of Health Terengganu Malaysia
2 shared publicationsNor Rizan Kamaluddin
Cancer Research Centre Institute for Medical Research, National Institutes of Health, Ministry of Health Selangor Malaysia
2 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Cell Nature and Science Publisher in Nature Cell and Science
- Vol. 4 (3) , e00026
Patient-Derived Vs IPSC-Derived Organoids: Complementary Platforms for Translational and Regenerative Medicine
Three-dimensional (3D) organoid cultures have transformed the way researchers bridge the gap between conventional two-dimensional (2D) systems and living tissue. Here, we compare the two organoid platforms that now dominate biomedical research—patient-derived organoids (PDOs) and induced pluripotent stem cell (iPSC)-derived organoids—and consider how combining their strengths might shape the future of translational and regenerative medicine. PDOs retain a donor's genetic, histopathological and phenotypic features, which makes them well suited to rapid, clinically relevant modelling of cancer, infectious disease and fibrosis; their main drawbacks are limited tissue availability, dependence on animal-derived matrices, and an incomplete tumour microenvironment. iPSC-derived organoids, by contrast, can be expanded almost indefinitely and are readily amenable to genetic manipulation, making them attractive for developmental and rare disease research, although they tend to remain immature and are costly to produce. We review several emerging approaches that address these shared limitations—co-culture and organoid-on-a-chip systems, multi-omics integration, and vascularised assembloids—alongside the ethical and regulatory questions that both platforms raise. Rather than competing technologies, we argue that PDOs and iPSC-derived organoids are best treated as complementary tools, and that hybrid models combining patient specificity with scalability offer a promising way forward. We also discuss the limitations of this narrative review, including its non-systematic search strategy.
- 1 September 2026
- Published by Cell Nature and Science Publisher in Nature Cell and Science
- Vol. 4 (3) , e00026
Open AccessPatient-Derived Vs IPSC-Derived Organoids: Complementary Platforms for Translational and Regenerative Medicine
Three-dimensional (3D) organoid cultures have transformed the way researchers bridge the gap between conventional two-dimensional (2D) systems and living tissue. Here, we compare the two organoid platforms that now dominate biomedical research—patient-derived organoids (PDOs) and induced pluripotent stem cell (iPSC)-derived organoids—and consider how combining their strengths might shape the future of translational and regenerative medicine. PDOs retain a donor's genetic, histopathological and phenotypic features, which makes them well suited to rapid, clinically relevant modelling of cancer, infectious disease and fibrosis; their main drawbacks are limited tissue availability, dependence on animal-derived matrices, and an incomplete tumour microenvironment. iPSC-derived organoids, by contrast, can be expanded almost indefinitely and are readily amenable to genetic manipulation, making them attractive for developmental and rare disease research, although they tend to remain immature and are costly to produce. We review several emerging approaches that address these shared limitations—co-culture and organoid-on-a-chip systems, multi-omics integration, and vascularised assembloids—alongside the ethical and regulatory questions that both platforms raise. Rather than competing technologies, we argue that PDOs and iPSC-derived organoids are best treated as complementary tools, and that hybrid models combining patient specificity with scalability offer a promising way forward. We also discuss the limitations of this narrative review, including its non-systematic search strategy.
- Open Access
- 2 March 2026
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 14 (3)
Single Nucleotide Polymorphism Microarray Analysis Unveils Copy‐Number Abnormalities and Genetic Heterogeneity in Malaysian Childhood B‐Cell Precursor Acute Lymphoblastic Leukemia
Introduction: B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL) is a prevalent pediatric hematologic malignancy characterized by diverse chromosomal aberrations that significantly influence its prognosis. This study aimed to comprehensively characterize the genomic landscape of BCP‐ALL in 55 Malaysian patients with BCP‐ALL. Methods: Single‐nucleotide polymorphism (SNP) 6.0 microarray and multiplex ligation‐dependent probe amplification were utilized to characterize and validate copy‐number abnormalities involving key oncogenes, respectively. Results: The SNP 6.0 microarray identified 191 copy‐number abnormalities in 55 patients, including common subtypes such as hyperdiploidy ( n = 14/191, 7.3%), hypodiploidy ( n = 2/191, 1.1%), and various copy‐number abnormalities such as interstitial (23.0%), terminal (17.2%), focal (37.1%), and intragenic (18.0%). Notably, intrachromosomal amplification of chromosome 21 (iAMP21) was not observed, suggesting its rarity in this cohort. Comparison with conventional cytogenetic techniques, including Trypsin‐Leishman's banding karyotyping, fluorescent in situ hybridization (FISH), and reverse transcription‐polymerase chain reaction (RT‐PCR), revealed superior resolution of the SNP 6.0 microarray in detecting submicroscopic copy‐number abnormalities. Furthermore, MLPA confirmed abnormalities in several oncogenes, including CDKN2A/B , EBF1 , ERG , ETV6 , IKZF1 , JAK2 , and PAX5 . Conclusion: This study demonstrates the utility of combined SNP 6.0 microarray and MLPA in providing a comprehensive and refined understanding of the genetic landscape of BCP‐ALL in the Malaysian population. This understanding may facilitate risk stratification and the development of personalized treatment strategies.
- 2 March 2026
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 14 (3)
Open AccessSingle Nucleotide Polymorphism Microarray Analysis Unveils Copy‐Number Abnormalities and Genetic Heterogeneity in Malaysian Childhood B‐Cell Precursor Acute Lymphoblastic Leukemia
Introduction: B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL) is a prevalent pediatric hematologic malignancy characterized by diverse chromosomal aberrations that significantly influence its prognosis. This study aimed to comprehensively characterize the genomic landscape of BCP‐ALL in 55 Malaysian patients with BCP‐ALL. Methods: Single‐nucleotide polymorphism (SNP) 6.0 microarray and multiplex ligation‐dependent probe amplification were utilized to characterize and validate copy‐number abnormalities involving key oncogenes, respectively. Results: The SNP 6.0 microarray identified 191 copy‐number abnormalities in 55 patients, including common subtypes such as hyperdiploidy ( n = 14/191, 7.3%), hypodiploidy ( n = 2/191, 1.1%), and various copy‐number abnormalities such as interstitial (23.0%), terminal (17.2%), focal (37.1%), and intragenic (18.0%). Notably, intrachromosomal amplification of chromosome 21 (iAMP21) was not observed, suggesting its rarity in this cohort. Comparison with conventional cytogenetic techniques, including Trypsin‐Leishman's banding karyotyping, fluorescent in situ hybridization (FISH), and reverse transcription‐polymerase chain reaction (RT‐PCR), revealed superior resolution of the SNP 6.0 microarray in detecting submicroscopic copy‐number abnormalities. Furthermore, MLPA confirmed abnormalities in several oncogenes, including CDKN2A/B , EBF1 , ERG , ETV6 , IKZF1 , JAK2 , and PAX5 . Conclusion: This study demonstrates the utility of combined SNP 6.0 microarray and MLPA in providing a comprehensive and refined understanding of the genetic landscape of BCP‐ALL in the Malaysian population. This understanding may facilitate risk stratification and the development of personalized treatment strategies.
- Open Access
- 1 March 2026
- Vol. 14 (3) , e70182
Single Nucleotide Polymorphism Microarray Analysis Unveils Copy-Number Abnormalities and Genetic Heterogeneity in Malaysian Childhood B-Cell Precursor Acute Lymphoblastic Leukemia.
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is a prevalent pediatric hematologic malignancy characterized by diverse chromosomal aberrations that significantly influence its prognosis. This study aimed to comprehensively characterize the genomic landscape of BCP-ALL in 55 Malaysian patients with BCP-ALL. Single-nucleotide polymorphism (SNP) 6.0 microarray and multiplex ligation-dependent probe amplification were utilized to characterize and validate copy-number abnormalities involving key oncogenes, respectively. The SNP 6.0 microarray identified 191 copy-number abnormalities in 55 patients, including common subtypes such as hyperdiploidy (n = 14/191, 7.3%), hypodiploidy (n = 2/191, 1.1%), and various copy-number abnormalities such as interstitial (23.0%), terminal (17.2%), focal (37.1%), and intragenic (18.0%). Notably, intrachromosomal amplification of chromosome 21 (iAMP21) was not observed, suggesting its rarity in this cohort. Comparison with conventional cytogenetic techniques, including Trypsin-Leishman's banding karyotyping, fluorescent in situ hybridization (FISH), and reverse transcription-polymerase chain reaction (RT-PCR), revealed superior resolution of the SNP 6.0 microarray in detecting submicroscopic copy-number abnormalities. Furthermore, MLPA confirmed abnormalities in several oncogenes, including CDKN2A/B, EBF1, ERG, ETV6, IKZF1, JAK2, and PAX5. This study demonstrates the utility of combined SNP 6.0 microarray and MLPA in providing a comprehensive and refined understanding of the genetic landscape of BCP-ALL in the Malaysian population. This understanding may facilitate risk stratification and the development of personalized treatment strategies.
- 1 March 2026
- Vol. 14 (3) , e70182
Open AccessSingle Nucleotide Polymorphism Microarray Analysis Unveils Copy-Number Abnormalities and Genetic Heterogeneity in Malaysian Childhood B-Cell Precursor Acute Lymphoblastic Leukemia.
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is a prevalent pediatric hematologic malignancy characterized by diverse chromosomal aberrations that significantly influence its prognosis. This study aimed to comprehensively characterize the genomic landscape of BCP-ALL in 55 Malaysian patients with BCP-ALL. Single-nucleotide polymorphism (SNP) 6.0 microarray and multiplex ligation-dependent probe amplification were utilized to characterize and validate copy-number abnormalities involving key oncogenes, respectively. The SNP 6.0 microarray identified 191 copy-number abnormalities in 55 patients, including common subtypes such as hyperdiploidy (n = 14/191, 7.3%), hypodiploidy (n = 2/191, 1.1%), and various copy-number abnormalities such as interstitial (23.0%), terminal (17.2%), focal (37.1%), and intragenic (18.0%). Notably, intrachromosomal amplification of chromosome 21 (iAMP21) was not observed, suggesting its rarity in this cohort. Comparison with conventional cytogenetic techniques, including Trypsin-Leishman's banding karyotyping, fluorescent in situ hybridization (FISH), and reverse transcription-polymerase chain reaction (RT-PCR), revealed superior resolution of the SNP 6.0 microarray in detecting submicroscopic copy-number abnormalities. Furthermore, MLPA confirmed abnormalities in several oncogenes, including CDKN2A/B, EBF1, ERG, ETV6, IKZF1, JAK2, and PAX5. This study demonstrates the utility of combined SNP 6.0 microarray and MLPA in providing a comprehensive and refined understanding of the genetic landscape of BCP-ALL in the Malaysian population. This understanding may facilitate risk stratification and the development of personalized treatment strategies.
- Open Access
- 1 September 2019
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 12, 7749-7756
Epidermal growth factor receptor (EGFR) gene alteration and protein overexpression in Malaysian triple-negative breast cancer (TNBC) cohort
Background: Epidermal growth factor receptor (EGFR) is a member of the ErbB family of tyrosine kinase receptor proteins that plays important roles in tumour cell survival and proliferation. EGFR has been reported to be overexpressed in up to 78% of triple-negative breast cancer (TNBC) cases suggesting it as a potential therapeutic target. The clinical trials of anti-EGFR agents in breast cancer showed low response rates. However, a subgroup of patients demonstrated response to EGFR inhibitors highlighting the necessity to stratify patients, who might benefit from effective combination therapy that could include anti EGFR-agents. Population variability in EGFR expression warrants systematic evaluation in specific populations. Purpose: To study EGFR alterations and expressions in a multi ethnic Malaysian TNBC patient cohort to determine the possibility of using anti-EGFR combinatorial therapy for this population. Patients and methods: In this study, we evaluated 58 cases of Malaysian TNBC patient samples for EGFR gene copy number alteration and EGFR protein overexpression using fluorescence in-situ hybridization (FISH) and immunohistochemistry (IHC) methods, respectively. Results: EGFR protein overexpression was observed in about 30% while 15.5% displayed high EGFR copy number including 5.17% gene amplification and over 10% high polysomy. There is a positive correlation between EGFR protein overexpression and gene copy number and over expression of EGFR is observed in ten out of the 48 low copy number cases (20.9%) without gene amplification. Conclusion: This study provides the first glimpse of EGFR alterations and expressions in a multi ethnic Malaysian TNBC patient cohort emphasising the need for the nationwide large scale EGFR expression evaluation in Malaysia.
- 1 September 2019
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 12, 7749-7756
Open AccessEpidermal growth factor receptor (EGFR) gene alteration and protein overexpression in Malaysian triple-negative breast cancer (TNBC) cohort
Background: Epidermal growth factor receptor (EGFR) is a member of the ErbB family of tyrosine kinase receptor proteins that plays important roles in tumour cell survival and proliferation. EGFR has been reported to be overexpressed in up to 78% of triple-negative breast cancer (TNBC) cases suggesting it as a potential therapeutic target. The clinical trials of anti-EGFR agents in breast cancer showed low response rates. However, a subgroup of patients demonstrated response to EGFR inhibitors highlighting the necessity to stratify patients, who might benefit from effective combination therapy that could include anti EGFR-agents. Population variability in EGFR expression warrants systematic evaluation in specific populations. Purpose: To study EGFR alterations and expressions in a multi ethnic Malaysian TNBC patient cohort to determine the possibility of using anti-EGFR combinatorial therapy for this population. Patients and methods: In this study, we evaluated 58 cases of Malaysian TNBC patient samples for EGFR gene copy number alteration and EGFR protein overexpression using fluorescence in-situ hybridization (FISH) and immunohistochemistry (IHC) methods, respectively. Results: EGFR protein overexpression was observed in about 30% while 15.5% displayed high EGFR copy number including 5.17% gene amplification and over 10% high polysomy. There is a positive correlation between EGFR protein overexpression and gene copy number and over expression of EGFR is observed in ten out of the 48 low copy number cases (20.9%) without gene amplification. Conclusion: This study provides the first glimpse of EGFR alterations and expressions in a multi ethnic Malaysian TNBC patient cohort emphasising the need for the nationwide large scale EGFR expression evaluation in Malaysia.